30 closest matches · ranked by relevance
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus — 8.2; 7.1 Months — p=0.00894
Esophageal Cancer
Primary: Number of Participants With Overall Response Rate (RR) — 44 participants
Esophageal Squamous Cell Carcinoma
Primary: Overall Survival — 7.23; 6.21 month — p=0.032
Esophageal Carcinoma
Primary: Overall Survival (OS) — 8.28; 6.24 months
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Esophageal Cancer · Squamous Cell Esophagus Cancer · Adenocarcinoma Esophagus
Primary: Overall Response Rate (ORR) — 0.08 proportion of participant
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Primary: Overall Survival (OS) — 8.08; 4.76; 6.67 months — p=0.7689
Esophageal Neoplasms
Primary: Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined…
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in All Participants — 8.4; 5.6 Months — p=0.0015
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Esophageal Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Assessed by the Investigator — 30.6; 20.6 percentage of participants — p=0.2114
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set — 8.6; 6.3 Months — p=0.0001
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Gastric Cancer
Primary: Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments — 4.4; 5.6 months — p=0.3158
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Esophageal Cancer
Primary: Overall Survival — 10.9; 8.4 months
Esophageal Cancer
Primary: Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS) — 5.39; 6.18 months — p=<0.0001
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Primary: PFS((Progression-Free Surviv) — 5.7; 5.5 months
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Esophageal Cancer · Gastroesophageal Junction Cancer
Primary: 2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer. — 20; 14; 1…
Esophageal Squamous Cell Carcinoma
Primary: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) — 13 Participants
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Esophagogastric Adenocarcinoma
Primary: 6-month Progression-free Survival (PFS) — 1.9 months
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months